Phase II trial of docetaxel (D) plus gefitinib (G) in elderly (≥70 years) patients with advanced stage non-small cell lung cancer (ANSCLC)

被引：0
|
作者：
Williams, C. [1 ]
Bepler, G. [1 ]
Begum, M. [1 ]
Chiappori, A. [1 ]
Arora, R. [1 ]
Haura, E. [1 ]
Antonia, S. [1 ]
Extermann, M. [1 ]
Simon, G. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7690
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [2] Docetaxel and gefitinib in the first-line treatment of elderly patients (≥ 70) with advanced non-small cell lung cancer (ANSCLC):: Results of phase II trial.
    Beple, G
    Williams, CC
    Chiappori, A
    Antonia, SJ
    Haura, EB
    Mahany, JJ
    Galloway, T
    Simon, GR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 659S - 659S
  • [3] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC).
    Stinchcombe, TE
    Socinski, MA
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, MT
    Mears, A
    Smith, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 685S - 685S
  • [4] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, T
    Socinski, M
    Choksi, J
    Bakri, K
    Taylor, M
    Tynan, M
    Mears, A
    Smith, C
    LUNG CANCER, 2005, 49 : S270 - S270
  • [5] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Stinchcombe, Thomas E.
    Buzkova, Petra
    Choksi, Janak
    Taylor, Mark
    Bakri, Kamal
    Gillenwater, Heidi
    Tynan, Maureen
    Mears, Andrea
    Jones, Paul E.
    Socinski, Mark A.
    LUNG CANCER, 2006, 52 (03) : 305 - 311
  • [6] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [7] Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Kimura, Tatsuo
    Mitsuoka, Shigeki
    Kyoh, Shigenoir
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kodama, Toyoki
    Ichimaru, Yukikazu
    Yana, Takashi
    Hirata, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 371 - 375
  • [8] Phase II trial of gefitinib in Chinese female patients with advanced non-small cell lung cancer
    Deng, J.
    Fang, W. J.
    Zhang, X. C.
    Chen, J.
    Qian, J.
    Mou, H. B.
    Xu, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
    Eager, R. M.
    Cunningham, C. C.
    Senzer, N.
    Richards, D. A.
    Raju, R. N.
    Jones, B.
    Uprichard, M.
    Nemunaitis, J.
    CLINICAL ONCOLOGY, 2009, 21 (06) : 464 - 472
  • [10] Preliminary results of a phase II trial of Docetaxel (D) and Gemcitabine (G) in advanced Non-Small Cell Lung Cancer (NSCLC) in elderly and/or unfit patients (PTS)
    Buffoni, Lucio
    Grillo, Raffaella
    Barone, Carla
    Dongiovanni, Diego
    Gaspari, Fabio
    Giacobino, Alice
    Consito, Lorena
    Ciuffreda, Libero
    Schena, Marina
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S668 - S668
12345